Outsourced Pharma Webinars

  1. Biologics Manufacturing - Is Your Company Ready?
    3/9/2017

    This webcast will not only reveal the current trends and challenges in Biologics manufacturing, but also new business models and how technology can drive high quality and operational efficiency. 

  2. What Paper Informed Consent Isn’t Offering You… And Why Top Pharma Is Turning to eConsent
    3/8/2017

    Why Top Pharma is turning to Electronic Informed Consent (eConsent) to exceed in these areas.

  3. The World’s Best eCOA Body Map: How Patients Improved Symptom Location Reporting
    3/7/2017

    The burden of ineffective and inefficient body maps creates risks that can impact data quality. We knew we could come up with something much better - for all stakeholders.

  4. The Practical Application Of Home Healthcare
    10/4/2016

    Recruiting patients and retaining their participation in a clinical trial remain the biggest challenges faced by pharmaceutical companies when developing new medicines. For a patient, participation in a clinical trial can be stressful and burdensome, resulting in one in four patients dropping out of a clinical trial prior to completion. With sponsors facing tight-timelines, increased regulatory scrutiny and spiralling budgets the desire to address these challenges has never been more prominent.

  5. Integrating Safety And Immunogenicity Assessments Into The Biopharma Preclinical Development Process
    9/27/2016

    Efficacy, safety, immunogenicity and manufacturability issues play a large role in the high attrition rate of biopharmaceutical candidates each year. To help reduce the risk of failure, tools to address the developability of preclinical candidates have been established.

  6. The Implications Of Inaccurate Forecasting In Biologic Drug Substance Manufacturing And Strategies To Mitigate Risks
    9/2/2016

    The biopharmaceutical market is undergoing tremendous transformation. Speed to develop and manufacture product has become a critical driver with increased competition and the pressure to be first to market. New process technologies, advances in cell line development and more targeted and complex therapeutic classes have created a challenging biopharmaceutical manufacturing environment with new capacity requirements.

  7. Innovations In E-Consent: Reducing Regulatory Risk While Improving Participant Comprehension
    6/16/2016

    Informed consent has a major impact on regulatory compliance, enrollment rates and expenses across the life of your study. Yet the traditional paper-based process has transformed informed consent into one of the most cited deficiencies.

  8. The Challenges Of Demand Forecast Accuracy For New Drug Launches
    6/13/2016

    This webinar discusses how achieving accurate demand forecasts is extremely challenging, especially for new drug launches, and what other pharmaceutical companies are doing to overcome those challenges.

  9. Expression Of Next Generation Biologics Requires Next Generation Expression Systems
    6/2/2016

    Next generation biologics include, but are not limited to, novel antibody formats or antibody derived molecules that are translating into promising next generation therapeutics.  Such highly diverse molecule formats demand a range of expression platforms in order to optimize production yields and quality. To address the complexity of these novel compounds, Lonza offers both mammalian and microbial expression platforms.

  10. eCOA Essentials: 1 Hour To Higher Quality Data
    5/5/2016

    The industry's shift from paper to electronic Clinical Outcome Assessments (eCOA) in clinical trials is happening at dizzying speeds.